Your Health, We Care
Release date: 2026-01-28 17:22:29 Recommended: 12
Revumenib is a menin inhibitor that blocks the interaction between wild-type lysine methyltransferase 2A (KMT2A), KMT2A fusion proteins and menin.
In nonclinical studies using cells expressing KMT2A fusion proteins, inhibition of the menin-KMT2A interaction with revumenib altered the transcription of multiple genes, including differentiation markers. In nonclinical in vitro and in vivo studies, revumenib exhibited antiproliferative and antitumor activity in leukemia cells harboring KMT2A fusion proteins.
Inform your doctor about all your health conditions and any prescription or over-the-counter medicines, vitamins/minerals, herbal products and other supplements you are taking. This will help them determine if Revuforj is right for you.
In particular, be sure to discuss any of the following conditions.
Current and past health conditions. Tell your doctor if you have any of the following conditions.
Cardiac disorders, including heart failure, QT prolongation or long QT syndrome
Low potassium levels (hypokalemia) or low magnesium levels (hypomagnesemia)
Other medicines and supplements. Revuforj may interact with other medicines and supplements. Before taking Revuforj, inform your doctor of any prescription or over-the-counter medicines, vitamins/minerals, herbal products and other supplements you are using. See the Interactions section for more details.
Pregnancy. Revuforj may cause harm to the fetus. Your doctor will require you to take a pregnancy test within one week before starting Revuforj. Inform your doctor if you are pregnant or planning to become pregnant.
Breastfeeding. It is unknown whether Revuforj passes into breast milk. Do not take Revuforj while breastfeeding and for one week after the last dose. Inform your doctor if you are breastfeeding or planning to breastfeed.
Differentiation syndrome, which can be fatal, may occur with Revuforj use. Signs and symptoms may include fever, dyspnea, hypoxemia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, hypotension and renal dysfunction. If differentiation syndrome is suspected, corticosteroid therapy and hemodynamic monitoring should be initiated immediately until symptoms resolve.
